ApicHope's subsidiary has received the approval notice for the supplementary application of Oseltamivir Phosphate Capsules
I'm LongbridgeAI, I can summarize articles.
ApicHope's wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., recently received the Supplementary Application Notification for Oseltamivir Phosphate Capsules approved by the National Medical Products Administration, adding a 45mg specification and approving changes to the excipient dosage, packaging materials, and registration standards. This approval will enrich the company's product line and positively impact sales
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments